Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Cellectis to Report First Quarter Financial Results on May 12, 2025
04:30pm, Tuesday, 06'th May 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
04:30pm, Monday, 28'th Apr 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
09:00am, Tuesday, 22'nd Apr 2025
Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
10:36am, Friday, 14'th Mar 2025
Cellectis S.A. (NASDAQ:CLLS ) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO C
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
06:07pm, Thursday, 13'th Mar 2025
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and OD
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
04:30pm, Friday, 07'th Mar 2025
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
01:30am, Monday, 24'th Feb 2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis: Poised To Start Answering Questions In 2025
03:08pm, Thursday, 12'th Dec 2024
Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a ri
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
04:30pm, Tuesday, 05'th Nov 2024
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
01:59pm, Tuesday, 05'th Nov 2024
Cellectis S.A. (NASDAQ:CLLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Arthur Stril - Interim Chief Financial Officer Andre Choulika - Chief Executive Officer
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
04:30pm, Monday, 04'th Nov 2024
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
04:30pm, Wednesday, 30'th Oct 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
02:00am, Tuesday, 22'nd Oct 2024
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
04:30pm, Tuesday, 03'rd Sep 2024
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
